CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling

CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling

Abstract Overall response rates in advanced Non-Small Cell Lung Cancer (NSCLC) remains low. Thus, novel molecular targets, tailored drugs and/or drug combinations are needed. Casein Kinase-2 (CK2) is a constitutively active and frequently over-expressed enzyme which fosters tumor survival, prolifera...

Full description

Bibliographic Details
Main Authors: Ying Yi, Lingfeng Dai, Yaqin Lan, Changyuan Tan, Dania M. Vázquez-Blomquist, Guirong Zeng, Dejian Jiang, Ke Yang, Silvio E. Perea, Yasser Perera
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Scientific Reports
Subjects:
CK2
CPP-based drug
Peptide inhibitor
Target therapy
NSCLC
Protein kinase
Online Access:https://doi.org/10.1038/s41598-024-75990-1

Internet

https://doi.org/10.1038/s41598-024-75990-1

Similar Items